Top Markets
#1 Akedo Akedo +59.38%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.41%
#4 Velvet Velvet +39.92%
#5 Black Phoenix Black Phoenix +34.56%
#6 Ο„emplar Ο„emplar +23.53%
#7 Ribbita by Virtuals Ribbita by Virtuals +17.77%
#8 Cross Cross +15.77%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.57%
#10 Bitway Bitway +15.46%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Psyence Group Inc. Psyence Group Inc.

Psyence Group Inc.

PSYG
Rank in Stocks #38237
Psyence Group Inc. is a life sciences biotechnology company primarily engaged... Psyence Group Inc. is a life sciences biotechnology company primarily engaged in the commercial cultivation and production of psilocybin mushrooms. This naturally sourced psilocybin is intended for therapeutic applications, addressing a broad spectrum of mental health conditions and other medical ailments. The company is actively formulating pharmaceutical-grade psilocybin treatments designed to mitigate psychological trauma and recognized disorders such as anxiety, depression, post-traumatic stress disorder (PTSD), and the emotional distress linked to grief and bereavement. Furthermore, Psyence Group develops, distributes, and sells over-the-counter functional mushroom nutraceuticals, entirely free of psilocybin, under its GOODMIND brand. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Share Price
$0.08765138
Last synced: 2025-12-23
Market Cap
$1.11M
Change (1 day)
0.45%
Change (1 year)
-28.78%
Country
CA
Trade Psyence Group Inc. (PSYG)

Category

Healthcare
P/E ratio for Psyence Group Inc. (PSYG)
P/E ratio as of 2026 TTM: 0
According to Psyence Group Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Psyence Group Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 40.73 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 29.64 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 123.01 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 36.58 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.